Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of Multiple Myeloma

Nammi Therapeutics, Inc. announced that the FDA has granted orphan drug designation to its lead program, QXL138AM, for the treatment of multiple myeloma.